Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology)

Inal, Ali; Kos, F.; Algin, Efnan; Yildiz, Ramazan; Berk, Veli; Unek, Ilkay; Colak, Dilsen; Dane, Faysal; Geredeli, Caglayan; Isikdogan, Abdurrahman

doi:10.5114/wo.2014.43933

Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology)

Atıf İçin Kopyala

Inal A., Kos F. T., Algin E., Yildiz R., Berk V., Unek I. T., ...Daha Fazla

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, cilt.19, sa.2, ss.125-129, 2015 (ESCI)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 19 Sayı: 2
Basım Tarihi: 2015
Doi Numarası: 10.5114/wo.2014.43933
Dergi Adı: WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
Sayfa Sayıları: ss.125-129
Gazi Üniversitesi Adresli: Evet

Özet

Aim of the study: Systemic chemotherapy for patients with pancreatic cancer has limited impact on overall survival (OS). Patients eligible for chemotherapy should be selected carefully. The aim of the study was to search for prognostic factors for survival in patients with gemcitabine (Gem)-refractory or with gemcitabine and cisplatin (GemCis)-refractory advanced pancreatic cancer.